Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2018 · 10-Q
Revenue$132.39M$132.39M+28,996.9% vs Q1 2017 Net Income$104.24M$104.24MN/M vs Q1 2017 EPS Diluted$3.04$3.04N/M vs Q1 2017 Operating Income$102,025,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived$55,790,000N/M Margins · derivedOperating margin77.1%+5114.9 pt vs Q1 2017
Net margin78.7%+4912.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end